trial

The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects

NCTId NCT01600885
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 16 (actual)
Sponsored by Yale University
Primary completion 2014-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
16 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2008-08
Primary completion
2014-12
Eligibility
ALL · 21 Years · 45 Years

Interventions & indications

Drugs
Guanfacine

Sponsors

Yale UniversityLead Sponsor
VA Office of Research and DevelopmentCollaborator

Investigators

2
John W. Newcomer, M.D.Principal Investigator
Naomi R Driesen, Ph.D.Study Director

Sites

3 total
New Haven, United StatesNew Haven, United StatesWest Haven, United States

Facts & assertions

4 sourced
Enrollment
16
Phase
NA
Primary Completion Date
2014-12
Status
COMPLETED
relationships
The graph out of here
drug
Guanfacine
drug
lead_sponsor
Yale University
company
collaborator
VA Office of Research and Development
company
indication
NMDA Receptor Function
indication
Schizophrenia
indication
investigator
John W. Newcomer, M.D.
person
Naomi R Driesen, Ph.D.
person